Fourteen days
On July 23, an Israeli investor named Nissim Daniel bought a quarter of a Nasdaq-listed company for $951,425.
Four days later he demanded that four of its five directors be removed. The company answered by selling stock to someone else, which would have shrunk his stake. He took it to court and won an injunction freezing the sale. They settled, and he got four of seven board seats.
Then, three days after winning, he sold every share he owned.
That sequence makes no sense on its own. It makes complete sense once you understand how this company funds itself, so start there.
The machine
On September 10, 2025, Wearable Devices put out a press release: "Wearable Devices Secures U.S. Patent for Breakthrough Voice and Gesture Control Technology."
The stock had closed at $3.06. It opened at $20.97 on 96.7 million shares and reached $34.20 two days later.
Then this happened:
| Date | Filing | What it did |
|---|---|---|
| Sep 12, 2025 | Prospectus supplement | 440,000 shares plus 560,000 pre-funded warrants |
| Sep 15, 2025 | Prospectus supplement | 440,000 shares plus 230,000 pre-funded warrants |
| Sep 25, 2025 | Prospectus supplement | A facility to sell up to $7,400,000 of stock |
Three offerings in fifteen days, directly into the spike.
It worked, as corporate finance. Shareholders' equity went from $3,860,000 to $18,553,000 in a year. The company turned a press release into a balance sheet.
The share count is the receipt for who paid:
Then the stock gave it all back, falling 98% to $0.63 by June 2026.
This is the machine, and everything else follows from it
A company with $647,000 of annual revenue and an $8,107,000 annual loss cannot fund itself from operations. It funds itself by selling stock into its own announcements.
That is legal, disclosed, and normal for pre-revenue companies with real patents. It also means the buyers of every spike are the people paying for the company, and there have now been two.
An investor who understands that machine has two choices. Fight it, or use it.
Three parties, and the one thing everyone gets wrong
Get the cast straight first, because almost all the confusion here comes from collapsing three parties into two.
| Who | What they are | What they walked away with |
|---|---|---|
| Wearable Devices | The company | $3.3 million cash, a new seven-person board, a $12 million backstop |
| Nissim Daniel, via J.B.D Innovation | The activist | About $1.6 million cash, four of seven board seats, no shares |
| An unnamed institutional investor | Bought the July share issue | 240,000 shares plus 1,760,000 warrants |
The warrants were never the activist's
Those 1,760,000 warrants belong to the third party, the institutional investor. The ordinary ones exercise at $3.16.
Nissim Daniel holds no warrants and no shares. He went to court to block the deal that created them. What he holds instead is a promise to lend $12 million, at a price nobody has agreed yet.
And nobody forced him to sell. No agreement required it. He chose to.
The raid
July 23. Daniel buys 543,361 shares, 24.82% of the company, for $951,425. About $1.75 a share. He files a Schedule 13D, the activist form.
July 27. He demands a shareholder meeting to change the rules on removing directors, remove four of the five sitting directors, install four of his own, and pay them. Read together, that is not a request for influence. It is a request for the board.
July 31. The company sells shares and warrants to a single unnamed institutional investor. Against 2,189,469 shares in existence, the deal could add 2,000,000 more:
| Instrument | Number | Price | Cash |
|---|---|---|---|
| Ordinary shares | 240,000 | $3.285 | $788,400 |
| Pre-funded warrants | 760,000 | $3.2849 | $2,496,524 |
| Raised on closing | $3,284,924 | ||
| Ordinary warrants | 1,000,000 | $3.16 to exercise | $3,160,000 if used |
New shares in friendly hands shrink a hostile holder's percentage. Daniel's stake fell from 17.42% to 15.50% without him selling anything.
August 2. He wins an interim order from the Haifa District Court freezing the placement and any change to the company's capital structure. For five days, an outside shareholder had legally frozen this company's ability to issue stock.
August 7. They settle.
| He got | The company got |
|---|---|
| Two directors resign | The demand withdrawn, irrevocably |
| Four of his nominees appointed, to a board expanded to seven | The court case dismissed |
| A two-year standstill on influencing governance | |
| A $12,000,000 financing commitment from him |
His four nominees are Oz Adler, Gabriel Kabazo, Hila Kiron Revach and Avichay Vardi. All qualify as independent under Nasdaq rules. Not one comes from wearables, neurotech or consumer hardware: they are accountants, CFOs and lawyers whose common thread is small-cap capital markets, and one has served as a court-appointed trustee in insolvency proceedings.
August 10 and 11. Daniel sells everything, at weighted averages of $3.76 and $2.97.
The final two days alone returned $1,105,251 on the 315,361 shares sold, against the $835,859 J.B.D originally put in. He had already sold 162,000 shares before those two days started.
Why he sold, and what he kept
Read as a sequence, selling three days after winning is baffling. Read as a strategy, it is the obvious move.
A 24.82% stake in a company like this looks powerful and is not:
| What he held | What he swapped it for |
|---|---|
| Dilutable at will, as the July placement proved | No equity left. The share count can triple and it costs him nothing |
| Effectively unsellable: 381,361 shares was eight full days of the stock's normal volume | About $1.6 million in cash, out of the burn |
| No control. 24.82% votes; it does not decide | Four of seven board seats |
| A quarter of a $6.6 million annual burn was his | A $12 million convertible commitment that ranks above equity |
On the day he signed the settlement, J.B.D committed irrevocably, for 24 months, to lend the company not less than $12,000,000 if the board decides it cannot fund the next two years. The form is debt convertible into shares. And the terms are the story:
The structure and commercial terms ... including the amount and timing of funding, interest rate, maturity, repayment terms, conversion mechanics ... will be negotiated and agreed in good faith between JBD and the Board then in office, including the directors appointed pursuant to the Cooperation Agreement.
The price at which that $12 million becomes shares has not been set. It gets negotiated later, between J.B.D and a board on which four of seven directors are J.B.D's nominees.
The sentence that explains everything
If you expect to buy a large piece of a company cheaply later, you do not want to be holding expensive shares in it now.
Every share he held at $3.76 would have been diluted by his own conversion. Selling was not abandoning the position. It was clearing the way for it.
Lending on terms that convert into ownership, while holding board seats, is a recognised structure called loan-to-own. It is legal, common, and fully disclosed here.
We are describing the shape of the arrangement, not anyone's intentions, and no filing states them. He may simply have taken a profit and left a backstop behind. The two-year standstill genuinely cuts against the aggressive reading. Both readings fit the same documents.
Who paid for it
| Put in | Got out | |
|---|---|---|
| Nissim Daniel | $951,425 | Over $1.1 million from the final two days alone, plus earlier sales |
| The company | Nothing | $3.3 million cash and a $12M backstop |
| The July placement investor | $3.3 million | Warrants currently worthless at a $3.16 strike |
| Existing shareholders | Nothing | Paid for all of it in dilution |
Is that farming retail? Not in the sense of anything improper. Every step was disclosed, the activist took real legal risk, and the company got money it needs.
But look at the effect rather than the intent. 707,463 shares became 2,460,394 in eighteen months, and the people who bought the spikes funded it. That is the mechanism to understand. Not a conspiracy, and not free money either.
What moves it from here
The balance sheet is genuinely unusual: $19.53 million of current assets against $1.44 million of debts, for a company valued at $7.4 million. That is 42 cents for every dollar of cash inside it.
Either the market is wrong and you are buying cash at a discount, or the market is right and a discount to cash is a forecast that the cash gets consumed rather than returned. The second has the stronger evidence, because that is exactly what happened to the last raise.
The four things that actually move it
1. The conversion price on the $12 million. The biggest unknown by far. Near the market when drawn, and this was a company getting funded. At a steep discount, or floating down with the stock, and it is something else. This one number settles the argument.
2. The warrants. 1,760,000 shares against 2,460,394 that exist, which is 72% more stock. Fully exercised, today's holders keep 58.3% of the company. They are worthless below $3.16, which is roughly where the stock sits, so they only bite on a rally.
3. Revenue. $647,000 against an $8.1 million loss. It grew 24% year over year, which sounds fine until you notice that is $125,000. A few million a year changes everything. Nothing else does.
4. Whether the next spike is met with another offering. It has been twice. The most convincing thing management could do on the next rally is nothing at all.
Where we think it goes
Grinds on and dilutes, roughly 55%, for one unglamorous reason: it is what the last two years already did, twice, and nothing since has broken the pattern.
The new board imposes capital discipline, about 20%. Four financially sophisticated directors change how money gets raised. The genuine wildcard, and it would show up plainly in the filings.
A licensing deal lands, about 15%. The patents are real and the category is real. Being paid by a large platform company is the credible outcome for a business this size, and it is almost entirely outside its control.
It runs out of road, about 10%. Low specifically because of the $12 million.
If you are trading it rather than holding it
Three numbers, from our own daily bars through August 12.
The 50-day average is $2.22 against a $3.02 close, so the stock sits 36% above it, not near it. A stop below that average is a 28% stop. The real support cluster is $2.77 to $2.87, where four different averages agree, with the structural floor at the $2.37 to $2.50 base. The 9-day average is $3.24 and price is below it, so a daily close back above $3.24 is the first genuine confirmation available.
And the number that governs the rest: ATR is $1.37, or 45.3% of the share price. A 7% stop is 0.15 of one average day's range, and would have been hit on four of the last eight sessions, including the day the stock closed up 47%. On a stock like this, a fixed percentage stop is a volatility filter wearing a risk-management costume.
The bottom line
A named investor spent $951,425 on a quarter of a company, fought it in court, won four of seven board seats, sold every share at roughly double his money, and left behind a promise to lend it more than the whole business is worth, at a price nobody has agreed yet, to a board he chose.
Every step was legal and every step was disclosed. The company came out better funded. The people who owned it came out owning less of it.
Whatever he concluded about the equity, he did not conclude it was the best place to be.
References
SEC filings (Wearable Devices Ltd., CIK 0001887673)
- Schedule 13D, July 27, 2026: J.B.D Innovation, Nissim Daniel, Victor Tshuva & Co., the 543,361 shares, the $951,425 and the demand letter
- Schedule 13D/A, August 12, 2026: the August 10 and 11 sales, the weighted average prices, and the zero position
- Form 6-K, July 27, 2026: the company confirming the demand to remove four of five directors
- Form 6-K, August 4, 2026: the Haifa District Court order freezing the placement
- Form 6-K, August 5, 2026: the placement terms, shares, pre-funded warrants and ordinary warrants
- Form 6-K, August 10, 2026: the Cooperation Agreement, the two-year standstill, the four director biographies, and the $12,000,000 convertible financing commitment
- Form 6-K, September 10, 2025: the patent release that preceded the move to $34.20
- Prospectus supplement, September 12, 2025 and September 15, 2025: the two registered direct offerings
- Prospectus supplement, September 25, 2025: the $7,400,000 at-the-market facility
- Complete EDGAR filing history
Notes on the numbers
Revenue, net loss, operating cash flow, assets, liabilities and shareholders' equity are FY2025 figures from the company's own filed XBRL data. Share counts are as disclosed: 707,463 at December 31, 2024, and 2,189,469 at June 17, 2026 per the Schedule 13D, which cites the company's Form 6-K of that date. The August 7 figure of approximately 2,460,394 is implied by the same 381,361 shares being reported as 15.50% rather than 17.42%, and is an estimate. The $1,105,251 realised on August 10 and 11 is calculated from the share counts and weighted average prices in the final Schedule 13D/A. The $3,284,924 raised on closing is calculated from the placement terms and matches the roughly $3.3 million the company reported. Prices, volumes, the 52-week range, all moving averages and the Average True Range are from The Desperate Trader's own market data, calculated through August 12, 2026 on 251 sessions. Verdicts, probability estimates and the reading of the strategy are our opinion.
This is research and commentary, not investment advice, and not an allegation of wrongdoing by any person or firm named. Every action described above was disclosed in public filings.